Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial

Abstract

Purpose: Personalized medicine strategies using genomic profiling are particularly pertinent for pancreas cancer. The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial was initially designed to exploit results from genome sequencing of pancreatic cancer under the auspices of the International Cancer Genome Consortium (ICGC) in Australia. Sequencing revealed small subsets of patients with aberrations in their tumor genome that could be targeted with currently available therapies. Experimental Design: The pilot stage of the IMPaCT trial assessed the feasibility of acquiring suitable tumor specimens for molecular analysis and returning high-quality actionable genomic data within a clinically acceptable timeframe. We screened for three molecular targets: HER2 amplification; KRAS wild-type; and mutations in DNA damage repair pathways (BRCA1, BRCA2, PALB2, ATM). Results: Tumor biopsy and archived tumor samples were collected from 93 patients and 76 were screened. To date 22 candidate cases have been identified: 14 KRAS wild-type, 5 cases of HER2 amplification, 2 mutations in BRCA2, and 1 ATM mutation. Median time from consent to the return of validated results was 21.5 days. An inability to obtain a biopsy or insufficient tumor content in the available specimen were common reasons for patient exclusion from molecular analysis while deteriorating performance status prohibited a number of patients from proceeding in the study. Conclusions: Documenting the feasibility of acquiring and screening biospecimens for actionable molecular targets in real time will aid other groups embarking on similar trials. Key elements include the need to better prescreen patients, screen more patients, and offer more attractive clinical trial options. Clin Cancer Res; 21(9); 2029–37. ©2015 AACR.

Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

“…Although significant progress has been made in diagnosis and treatment, PDAC is still a devastating disease with extremely high lethal rate, which is equal to the incidence of the disease (1-3). Thus, there is an urgent need for developing strategies in prediction of resectability, assessing the effect of chemotherapy and radiotherapy (4). Although medical image examinations like CT and ultrasound may provide much important information for tumor, it is still not sufficient to obtain complete data preoperatively.…”

Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie

“…Between 29-72% of patients had potentially actionable targets after sequencing with multiplex panels in results from several large cohorts (123)(124)(125)(126). The number of actionable targets is highly variable depending on the available compounds for treatment at a center and the number of mutations assessed in each panel.…”

Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?

“…Of the 76 patients who completed molecular evaluation, two mutations in BRCA2 and one in ATM were detected, translating into a rate of 3.9% (68). Whole exome sequencing was performed on 99 cases of tumor tissue from early stage (stages I and II) sporadic pancreatic adenocarcinoma and five mutations in ATM were detected (5.1%) but none in BRCA1/2 or other Fanconi Anemia related genes (69).…”